Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 12,454.80 -74.92 -0.60%
S&P 500 1,317.82 -2.86 -0.22%
Nasdaq 2,837.53 -1.85 -0.07%
Ticker Volume Price Price Delta
STOXX 50 2,161.87 +5.35 0.25%
FTSE 100 5,351.53 +1.48 0.03%
DAX 6,339.94 +24.05 0.38%
Ticker Volume Price Price Delta
Nikkei 8,580.39 +17.01 0.20%
TOPIX 722.11 -0.14 -0.02%
Hang Seng 18,713.40 +47.01 0.25%
Gold 1,571.20 +0.73%
EUR-USD 1.2517 -0.1227%
Nasdaq 2,837.53 -0.07%
DJIA 12,454.80 -0.60%
S&P 500 1,317.82 -0.22%
FTSE 100 5,351.53 +0.03%
STOXX 50 2,161.87 +0.25%
DAX 6,339.94 +0.38%
Oil (WTI) 90.86 +0.22%
U.S. 10-year 1.738% -0.039
BAC:US 7.15 +0.14%
FB:US 31.91 -3.39%
  • Exchange: ASE
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Medical-Drugs

Biota Holdings Ltd

Add to Portfolio

BTA:AU

0.7950 AUD 0.0150 1.85%

As of 02:10:50 ET on 05/25/2012.

Snapshot for Biota Holdings Ltd (BTA)

Open: 0.8000 Day's Range: 0.7900 - 0.8100 Volume: 706,521 Bid: 0.7850
Previous Close: 0.8100 52wk Range: 0.6900 - 1.1950 1-Yr Rtn: -32.63% Ask: 0.7950

Stock Chart for BTA

No chart data available.
  • BTA:AU 0.7950
  • 1D
  • 1M
  • 1Y
0.8100
Interactive BTA Chart

Previous Close

Key Statistics for BTA

Current P/E Ratio (ttm) -
Estimated P/E (06/2012) -
Earnings Per Share (AUD) (ttm) -0.1280
Est. EPS (AUD) (06/2012) -0.0780
Est. PEG Ratio -
Market Cap (M AUD) 144.97
Shares Outstanding (M) 182.35
Enterprise Value (M AUD) (ttm) 88.43
Enterprise Value/EBITDA (ttm) -
Price/Book (mrq) 2.1809
Price/Sale (ttm) -
Dividend Indicated Gross Yield 0.0000
Next Earnings Announcement 08/22/2012
More BTA Key Statistics mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Financials for BTA

  • Revenue
  • Net Income (M/AUD)
  • Profit Margin (%)
More BTA Income Statement Data
  • Total Assets
  • Total Liabilities (M/AUD)
  • Debt to Assets (%)
More BTA Balance Sheet Data
  • Operating
  • Investing
  • Financing (M/AUD)
More BTA Cash Flow Data

Company Profile & Key Executives for BTA

Biota Holdings Limited focuses on the research and development of new human drugs for the treatment of viral respiratory diseases. Biota's marketed products are used for the treatment of influenza along with an influenza diagnostic test kit. The Company is also developing products for the treatment of RSV and rhinovirus.

James Charles Fox "Jim"ChairmanPeter Chapman CookCEO/Managing Director
Damian T LismoreCFO/SecretarySimon TuckerVP:Research
More Company Profile & Key Executives for BTA

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisement
Advertisement
Advertisements